Clinical Trials

39 enrolled

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT01479842 2025-10-15

Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma

48 enrolled

Phase 1 Enrolling by invitation

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06788509 2025-10-10

A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

80 enrolled

LymphoidMyeloidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute

NCT02537613 2025-09-30

A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

54 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03535350 2025-09-30

Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma

Phase 1 Not yet recruiting

36 enrolled

CNS

Brain Neoplasms, Glioblastoma

NCT07169565 2025-09-11

Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia

21 enrolled

Waldenstrom Macroglobulinemia

NCT03424122 2025-08-21

INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

50 enrolled

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04876092 2025-08-21

A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL

45 enrolled

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03220022 2025-07-18

Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas

46 enrolled

Lymphoma, AIDS-Related

NCT02303392 2025-06-10

Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma

34 enrolled 14 charts

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT03400176 2025-05-16

VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib

39 enrolled 30 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03939182 2025-04-25

Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma

15 enrolled

Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT04781855 2025-02-28

Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation

Phase 1 Withdrawn

Leukemia, Lymphocytic, Chronic, B-Cell, Hematologic Neoplasms

NCT02743546 2025-02-03

Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma

Phase 1 Withdrawn

Bronchiolitis Obliterans Syndrome, Lymphoma, Follicular, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT02268851 2024-11-15

A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL

45 enrolled 13 charts

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT03136497 2024-09-23

A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

10 enrolled 14 charts

Lymphoma, Large B-Cell, Diffuse

NCT03422393 2024-07-05

Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib

24 enrolled

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Disease Progression

NCT03225716 2024-05-03

A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia

13 enrolled 13 charts

Waldenstrom Macroglobulinemia

NCT03525925 2024-03-18

Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid Tumors

16 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT04439006 2023-12-26

Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization

Classical hematologyMyeloidOther hematologic neoplasm

10 enrolled

Anemia, Aplastic, Monoclonal Gammopathy of Undetermined Significance, Myelodysplastic Syndromes, Hematologic Neoplasms

NCT02352558 2023-11-14

A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies

LymphoidMyeloidOther hematologic neoplasmPlasma cell

15 enrolled

Lymphoma, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT02309580 2023-05-09

Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma

14 enrolled

Recurrence, Lymphoma, T-Cell

NCT03876028 2023-01-31

Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients

10 enrolled

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT03454165 2023-01-04

A Study of BNC105P Combined With Ibrutinib

6 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02756247 2022-10-10

A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma

37 enrolled

Lymphoma, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT02553941 2022-10-06

Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome

Other hematologic neoplasm

21 enrolled

Leukemia, Myelomonocytic, Chronic

NCT01886859 2022-09-26

Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

27 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, B-Cell

NCT02419560 2022-05-24

Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL

37 enrolled

Recurrence, Lymphoma, Mantle-Cell

NCT01644253 2021-05-20

Phase 1b Safety and Efficacy Study of TRU-016

87 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, T-Cell, Peripheral

NCT02759016 2020-09-29

Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib

7 enrolled 8 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04043845 2020-02-05

ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies

Phase 1 Withdrawn

Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03301207 2019-12-05

A Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Participants With B Cell Malignancy

25 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02006485 2019-11-05

Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies

160 enrolled

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02556892 2019-08-14

A Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Other hematologic neoplasm

8 enrolled

Leukemia, Lymphoid

NCT02950220 2019-07-30

Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

2 enrolled